Comparative Pharmacology
Head-to-head clinical analysis: AVYCAZ versus CECLOR CD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVYCAZ versus CECLOR CD.
AVYCAZ vs CECLOR CD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVYCAZ is a combination of ceftazidime, a cephalosporin beta-lactam antibiotic, and avibactam, a non-beta-lactam beta-lactamase inhibitor. Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Avibactam protects ceftazidime from degradation by certain beta-lactamases, including Ambler class A, class C, and some class D enzymes.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
1 vial (ceftazidime 2g and avibactam 0.5g) IV over 2 hours every 8 hours.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
None Documented
None Documented
Ceftazidime: ~2.8 hours; avibactam: ~2.7 hours. Extended in renal impairment (e.g., CrCl <50 mL/min requires dose adjustment).
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
Ceftazidime: primarily renal (80-90% unchanged); avibactam: primarily renal (85-95% unchanged). Fecal excretion <1%.
Renal: ~80% unchanged; biliary/fecal: ~20%
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic